Table 2.
Superior frontal cortex MLA binding and Aβ ELISA levels by diagnostic groups
| Clinical Diagnosis |
CERAD Diagnosis |
||||||
|---|---|---|---|---|---|---|---|
| Variable | NCI | MCI | mAD | P value a | Not AD | AD§ | P value a |
| MLA, mean (SD) | 2.4 ± 1.0 (N=12) | 2.4 ± 1.5 (N=7) | 3.0 ± 1.4 (N=5) | 0.7 | 1.8 ± 0.7 (N=8) | 2.9 ±1.3 (N=16) | 0.079 |
| Aβ40*, mean (SD) | 2.3 ± 1.6 (N=5) | 2.5 ± 2.2 (N=8) | 4.3 ± 1.7 (N=7) | 0.1 | 1.7 ± 1.9 (N=8) | 4.0 ±1.6 (N=12) | 0.063 |
| Aβ42*, mean (SD) | 5.0 ± 2.5 (N=5) | 5.2 ±2.4 (N=8) | 7.3 ± 0.3 (N=7) | 0.022 | 4.1 ± 2.5 (N=8) | 7.1 ±0.4 (N=12) | 0.021 |
| Total Aβ*, mean (SD) | 5.1 ± 2.5 (N=5) | 5.3 ±2.4 (N=8) | 7.5 ± 0.4 (N=7) | 0.015 | 4.2 ± 2.4 (N=8) | 7.3 ±0.5 (N=12) | 0.015 |
§
Includes CERAD diagnosis of possible, probable, and definite AD
*
Aβ levels were log-transformed
a
Wilcoxon rank-sum test or Kruskal-Wallis test